Protein misfolding in Alzheimer's and Parkinson's disease: Genetics and molecular mechanisms

Neurobiology of Aging

Volumn 23, Issue 5, 2002, Pages 957-976

  Forloni, Gianluigi ^a   Terreni, Liana ^a   Bertani, Ilaria ^a   Fogliarino, Sergio ^a   Invernizzi, Roberto ^a   Assini, Andrea ^b   Ribizzi, Giuseppe ^b   Negro, Alessandro ^c   Calabrese, Elena ^d   Volonté, Maria Antonietta ^e   Mariani, Claudio ^f   Franceschi, Massimo ^g   Tabaton, Massimo ^b   Bertoli, Alessandro ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Clinica S Maria HSR   (Italy)

Author keywords

Amyloid; Parkin ubiquitin proteasome system (UPS); Presenilins; Synuclein

Indexed keywords

AMYLOID BETA PROTEIN; POLYGLUTAMINE; PRESENILIN 1; PROTEASOME; PROTEIN PRECURSOR; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; FAMILIAL DISEASE; GENETIC SCREENING; GENETICS; HUMAN; MOLECULAR MECHANICS; MUTATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING;

AGED; ALZHEIMER DISEASE; AMYLOID; CYSTEINE ENDOPEPTIDASES; HUMANS; LIGASES; MEMBRANE PROTEINS; MULTIENZYME COMPLEXES; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PRESENILIN-1; PRESENILIN-2; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; SYNUCLEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 0036752519     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00076-3     Document Type: Article

References (189)

1. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De Michele G.et al. A wide variety of mutations in the Parkin gene are responsible for autosomal recessive Parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8:1999;567-574.
2. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D.et al. Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69:1997;1196-1203.
3. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69:1997;1326-1329.
4. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E.et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:2000;239-252.
5. Aldudo J., Bullido M.J., Frank A., Valdiviero F. Missense mutation E318G of the presenilin 1 gene appears to be a non-pathogenic polymorphism. Ann. Neurol. 44:1998;433-439.
6. Alvarez R., Alvarez V., Lahoz C.H., Martinez C., Pena J., Sanchez J.M.et al. Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polimorphisms and late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 67:1999;733-736.
7. Alves-Rodriguez A., Gregori L., Figuiredo-Pereira M.E. Ubiquitin, cellular inclusions and their role in neurodegeneration. TINS. 21:1998;516-520.
8. Ancolio K., Marambaud P., Dauch P., Checler F. γ-Secretase-derived product of β-amyloid precursor protein is decreased by presenilin 1 mutations linked to familial Alzheimer's disease. J. Neurochem. 69:1997;2494-2499.
9. Ancolio K., Alves da Costa C., Ueda K., Checler F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285:2000;79-82.
10. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M.et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 52:1998;879-884.
11. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
12. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274:1999;33855-33858.
13. Bertoli A., Bertani I., Invernizzi R., Forloni G. Alpha-synuclein and dopaminergic degenaration in Parkinson's disease. Res. Adv. Neurochem. 1:2000;83-103.
14. Borchelt D.R., Thinakaran G., Eckman C., Lee M.K., Davenport F., Ratovitsky T.et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ 1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013.
15. Busztajn S., DeSouza R., McPhie D.L., Bermaqn S.A., Shioi J., Robakis N.K.et al. Overexpression in neurons of human presenilin 1 or a presenilin 1 familial Alzheimer disease mutant does not enhance apoptosis. J. Neurosci. 8:1999;9790-9799.
16. Campion D., Brice A., Dumanchin C., Puel M., Baulac M., De La Sayette V.et al. A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years. Neuroreport. 7:1996;1582-1584.
17. Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M.et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic, heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65:1999;664-670.
18. Chapman J., Wang N., Treves T.A., Korczyn A.D., Bornstein N.M. ACE, MTHFR, factor V Leiden, and ApoE polymorphisms in patients with vascular and Alzheimer's dementia. Stroke. 29:1998;1401-1404.
19. Checler F. The multiple paradoxes of presenilins. J. Neurochem. 76:2001;1621-1627.
20. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Gao J., Ross C.A.et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy body formation in Parkinson disease. Nat. Med. 7:2001;1144-1150.
21. Citron M., Vigo-Pelfrey C., Teplow D.B., Miller C., Schenk D., Johnston J.et al. Excessive production of amyloid β-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familia Alzheimer disease mutation. Proc. Natl. Acad. Sci. U.S.A. 91:1994;11993-11997.
22. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G.et al. Mutant presenilins of Alzheimer's disease production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 3:1997;67-72.
23. Citron M., Eckman C.B., Diehl T.S., Corcoran C., Ostaszewski B.L., Xia W.et al. Additive effect of PS1 and APP mutations on secretion of the 42-residue amyloid β-protein. Neurobiol. Dis. 5:1998;107-111.
24. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254.
25. Colley W.C., Sung T.C., Roll R., Jenco J., Hammond S.M., Altshuller Y.et al. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal re-organization. Curr. Biol. 7:1997;191-201.
26. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1998;1318-1320.
27. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97:2000;571-576.
28. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436:1998;309-312.
29. Crowther R.A., Daniel S.E., Goedert M. Characterization of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 292:2000;128-130.
30. Cruts M., Van Duijn C.M., Backhovens H., Hutton M., Hardy J., St. George-Hyslop P.H.et al. Estimation of the genetic contribution of presenilin 1 and 2 mutations in a population-based study of presenile Alzheimer disease. Hum. Mol. Genet. 7:1998;43-51.
31. Cummings C.J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A.et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 24:1999;879-892.
32. Czech C., Tremp G., Pradier L. Presenilins and Alzheimers's disease: biological functions and pathogenic mechanisms. Prog. Neurobiol. 60:2000;363-384.
33. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273:1998;9443-9449.
34. De Gioia L., Selvaggini C., Ghibaudi E., Diomede L., Bugiani O., Forloni G.et al. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem. 269:1994;7859-7862.
35. De Jonghe C., Cras P., Vanderstichele H., Cruts M., Vanderhoeven I., Smouts I.et al. Evidence that Aβ 42 plasma levels in presenilin 1 mutation carriers do not allow for prediction of their clinical phenotype. Neurobiol. Dis. 6:1999;280-287.
36. De Jonghe C., Cruts M., Rogaeva E.A., Tysoe C., Singleton A., Vanderstichele H.et al. Aberrant splicing in the presenilin 1 intron 4 mutation causes presenile Alzheimer's disease by increased a β 42 secretion. Hum. Mol. Genet. 8:1999;1529-1540.
37. De Martino G.N., Slaughter C.A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274:1999;22123-22126.
38. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.I., Stern M.B.et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 157:2000;1439-1445.
39. Eckman C.B., Mehte N.D., Crook R., Perez-Tur J., Prihar G., Pfeiffer E.et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of Abeta 42(43). Hum. Mol. Genet. 6:1997;2087-2089.
40. Favit A., Grimaldi M., Alkon D.L. Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway. J. Neurochem. 75:2000;1258-1263.
41. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature. 404:2000;394-398.
42. Fergusson J., Landon M., Lowe J., Dawson S.P., Layfield R., Hanger D.P.et al. Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci. Lett. 219:1996;167-170.
43. Forloni G., Chiesa R., Smiroldo S., Verga L., Salmona M., Tagliavini F.et al. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport. 4:1993;523-526.
44. Forloni G., Tagliavini F., Bugiani O., Salmona M. Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides. Prog. Neurobiol. 49:1996;287-315.
45. Forloni G. Neurotoxicity of β-amyloid and prion peptides. Curr. Opin. Neurol. 9:1996;492-500.
46. Forloni G., Lucca E., Angeretti N., Della Torre P., Salmona M. Amidation of beta-amyloid peptide strongly reduced the amyloidogenic activity without alteration of the neurotoxicity. J. Neurochem. 69:1997;2048-2054.
47. Forloni G., Bertani I., Calella A.M., Thaler F., Invernizzi R. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann. Neurol. 47:2000;632-640.
48. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:1996;259-272.
49. Forno L.S., Langston J.W. Lewy bodies and aging:relation to Alzheimer's disease and Parkinson's disease. Neurodegeneration. 2:1993;19-22.
50. Gandy S., Nastund J., Nordstedt C. Alzheimer's disease. Molecular consequence of presenilin 1 mutation. Nature. 411:2001;654-656.
51. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild-type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274:1999;7619-7622.
52. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I.et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
53. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2:2000;E115-E119.
54. Gomez-Isla T., Wasco W., Pettingel W.P., Gurubhagavatula S., Schmidt S.D., Jondro P.D.et al. A novel presenilin 1 mutation: increased β-amyloid and neurofibrillary changes. Ann. Neurol. 41:1997;809-813.
55. Gomez-Isla T., Growdon W.B., McNamara M.J., Nochlin D., Bird T.D., Arango J.C.et al. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain. 122:1999;1709-1719.
56. Grimaldi L.G., Casadei V., Ferri C., Veglia F., Licastro F., Annoni G.et al. Association of early-onset Alzheimer's disease with an interleukin-1 alpha gene polymorphism. Ann. Neurol. 47:2000;361-365.
57. Haass C., Hung A.Y., Selkoe D.J., Teplow D.B. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta protein precursor. J. Biol. Chem. 269:1994;17741-17748.
58. Han H., Weinreb P.H., Lansbury P.T. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol. 2:1995;163-169.
59. Harkany T., Abraham I., Konya C., Nyakas C., Zarandi M., Penke B.et al. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev. Neurosci. 11:2000;329-382.
60. Hashimoto M., Hsu L.J., Sisk A., Xia Y., Takeda A., Sundsmo M.et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799:1998;301-306.
61. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M.et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 10:1999;717-721.
62. Hattori N., Kitada T., Matsumine H., Asakawa S., Yamamura Y., Yoshino H.et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile Parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann. Neurol. 44:1998;935-941.
63. Hattori N., Matsumine H., Asakawa S., Kitada T., Yoshino H., Elibol B.et al. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem. Biophys. Res. Commun. 249:1998;754-758.
64. Helisalmi S., Hiltunen M., Mannerman A., Koivisto A.M., Lehtovista M., Alafuzorff I.et al. Is the presenilin 1 E318G missense mutation a risk factor for Alzheimer's disease? Neurosci. Lett. 278:2000;65-68.
65. Hochstrasser M. Ubiquitin-dependent protein degradation. Ann. Rev. Genet. 30:1996;405-439.
66. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P.et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and preselinin 1 transgenes. Nat. Med. 4:1998;97-100.
67. Houlden H., Baker M., McGowan E., Lewis P., Hutton M., Crook R.et al. Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS1 mutations that lead to exceptionally high amyloid-β concentrations. Ann. Neurol. 48:2000;806-808.
68. Hutton M., Busfield F., Wragg M., Crook R., Perez-Tur J., Clark R.F.et al. Complete analysis of the presenilin 1 gene in early-onset Alzheimer's disease. Neuroreport. 7:1996;801-805.
69. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 105:2001;891-990.
70. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275:2000;35661-35664.
71. Ishii K., Ii K., Hasegawa T., Shoji S., Doi A., Mori H. Increased Aβ 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS1 gene. Neurosci. Lett. 228:1997;17-20.
72. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A.et al. The precursor protein of non-Abeta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:1995;467-475.
73. Iwatsubo T., Yamaguchi H., Fujimuro M., Yokosawa H., Ihara Y., Trojanowski J.Q.et al. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148:1996;1517-1529.
74. Iwatsubo T. Amyloid β-protein in plasma as a diagnostic marker for Alzheimer's disease. Neorobiol. Aging. 19:1998;161-163.
75. Jahngen-Hodge J., Obin M.S., Gong X., Shang F., Nowell T.R., Gong J.et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J. Biol. Chem. 272:1997;28218-28226.
76. Jenco J.M., Rawlingson A., Daniels B., Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry. 37:1998;4901-4909.
77. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
78. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:1998;S72-S84.
79. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13:1998;S24-S34.
80. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273:1998;26292-26294.
81. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., Jakes R. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274:1999;25481-25489.
82. Jo E., McLaurin J., Yip C.M., St. George-Hyslop P., Fraser P.E. Alpha-synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275:2000;34328-34334.
83. Johnston J.A., Cowborn R.F., Norgren S., Wiehager B., Venizeios N., Winblad R.et al. Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. FEBS Lett. 354:1994;274-278.
84. Johnston J.A., Ward C.L., Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143:1998;188-198.
85. Kahle P.J., Leimer U., Haass C. Does failure of Parkin-mediated ubiquitination cause juvenile Parkinsonism? Trends Biochem. Sci. 25:2000;524-527.
86. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A.et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20:2000;6365-6373.
87. Kanda S., Bishop J.F., Eglitis M.A., Yang Y., Mouradian M.M. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience. 97:2000;279-284.
88. Katayama T., Imaizumi K., Sato N., Miyoshi K., Kudo T., Hitomi J.et al. Presenilin 1 mutations downregulate the signalling pathway of the unfolded protein response. Nat. Cell Biol. 1:1999;479-485.
89. Katayama T., Imaizumi K., Honda A., Yoneda T., Kudo T., Takeda M.et al. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin 1 mutations. J. Biol. Chem. 276:2001 Nov 16;43446-43454.
90. Kawarabayashi T., Younkin L., Saido T., Shoji M., Ashe K., Younkin S. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 31:2001;372-381.
91. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S.et al. Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature. 392:1998;605-608.
92. Ko L.W., Mehta N.D., Farrer M., Easson C., Hussey J., Yen S.et al. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75:2000;2546-2554.
93. Kolsh H., Ptok U., Bagli M., Papassotiropoulus A., Schmitz A., Barkow K.et al. Gene polymorphisms and interleukinb-1 alpha influence the course of Alzheimer's disease. Ann. Neurol. 49:2001;818-819.
94. Kosaka T., Imagawa M., Seki K., Arai H., Sasaki H., Tsuji S.et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at Abeta 42(43). Neurology. 48:1997;741-745.
95. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S.et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
96. Kuic L., Walter J., Multhaup G., Teplow D.B., Baumeister R., Romig H.et al. Separation of presenilin function in amyloid beta-peptide generation and endoproteolysis of notch. Proc. Natl. Acad. Sci. U.S.A. 97:2000;5913-5918.
97. Kwak S., Masaki T., Ishiura S., Sugita H. Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci. Lett. 128:1991;21-24.
98. Kwok J.B., Li Q.X., Hallupp M., Whyte S., Ames D., Beyreuther K.et al. Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta 42(43) peptide levels and induces apoptosis. Ann. Neurol. 47:2000;249-253.
99. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339:1998;1044-1053.
100. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15:2001;916-926.
101. Lee M., Hyun D., Halliwell B., Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76:2001;998-1009.
102. Lemere C., Lopera F., Kosik K., Lendon C., Ossa J., Saido T.et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ 42 deposition and severe cerebellar pathology. Nat. Med. 2:1996;1146-1150.
103. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
104. Levy-Lahad E., Wijsman E.M., Nemens E., Anderson L., Goddard K.A.B., Weber J.L.et al. A familial Alzheimer's disease locus on chromosome I. Science. 269:1997;970-973.
105. Lewis P.A., Perez-Tur J., Golde T.E., Hardy J. The presenilin 1 C92S mutation increased Aβ 42 production. Biochem. Biophys. Res. Commun. 277:2000;261-263.
106. Li Y.-M., Lai M.-T., Huang Q., Di Muzio-Mower J., Sardana M.K., Shi X.-P.et al. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6138-6143.
107. Lopez Salon M., Morelli L., Castano E.M., Soto E.F., Pasquini J.M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosci. Res. 62:2000;302-310.
108. Love S., Jenner P. Oxidative stress in neurological disease. Brain Pathol. 9:1999;55-56.
109. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M.et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. 155:1988;9-15.
110. Lowe J., McDermott H., Landon M., Mayer R.J., Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161:1990;153-160.
111. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T.et al. Association between early-onset Parkinson's disease and mutations in the Parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342:2000;1560-1567.
112. Manthorpe M., Fagnani R., Skaper S.D., Varon S. An automated colorimetric microassay for neuronotrophic factors. Brain Res. 390:1986;191-198.
113. Maruyama M., Ikeuchi T., Saito M., Ishikawa A., Yuasa T., Tanaka H.et al. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile Parkinsonism. Ann. Neurol. 48:2000;245-250.
114. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A.et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
115. McKhan G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspicies of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
116. McLaurin L., Yang D., Yip C.M., Fraser P.E. Review: modulating factors in amyloid-beta fibril formation. J. Struct. Biol. 130:2000;259-270.
117. McLean P.J., Kawamata H., Ribich S., Hyman B.T. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275:2000;8812-8816.
118. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194.
119. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:2001;589-594.
120. Mehta N.D., Refolo L.M., Eckman C., Sanders S., Yager D., Perez-Tur J.et al. Increased Aβ 42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. 43:1998;256-258.
121. Mezey E., Dehejia A., Harta G., Papp M.I., Polymeropoulos M.H., Brownstein M.J. Alpha-synuclein in neurodegenerative disorders: murderer or accomplice? Nat. Med. 4:1998;755-757.
122. Morett E., Bork P. A novel transactivation domain in Parkin. Trends Biochem. Sci. 24:1999;229-231.
123. Moynihan T.P., Ardley H.C., Nuber U., Rose S.A., Jones P.F., Markham A.F. The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7AP1. J. Biol. Chem. 274:1999;30963-30968.
124. Muller U., Bodeker R.H., Gerundt I., Kurz A. Lack of association between α1-anti-chymotrypsin polymorphism, Alzheimer's disease, and allele ε4 of apolipoprotein E. Neurology. 47:1996;1575-1577.
125. Murayama O., Tomita T., Nihonmatsu N., Murayama M., Sun X., Honda T. Enhancement of amyloid β 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett. 265:1999;61-63.
126. Myers A., Holmans P., Marshall H., Meyer D., Ramic D., Shears S.et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 290:2000;2304-2305.
127. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D.et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274:1999;9843-9846.
128. Nicoll J., Mrak R., Graham D., Stewart J., Wilcock G., MacGowan S.et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47:2000;283-285.
129. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C.et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by anhanced protofibril formation. Nat. Neurosci. 4:2001;887-893.
130. Okochi M., Eimer S., Bottcher A., Baumeister R., Romig H., Walter J.et al. A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in Caenorhabditis elegans and increases abeta 42 generation in human cells. J. Biol. Chem. 275:2000;40925-40932.
131. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology. 40:1990;S32-S39.
132. Orr H.T., Chung M.Y., Banfi S., Kwiatkowski T.J., Servadio A., Beaudet A.L.et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 4:1993;221.
133. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054.
134. Paik S.R., Shin H.J., Lee J.H., Chang C.S., Kim J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 340:1999;821-828.
135. Pericak-Vance M.A., Bass M.P., Yamaoka L.H., Gaskell P.C., Scott W.K., Terwedov H.A.et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA. 278:1997;1237-1241.
136. Perez RG, Zigmond MJ. Proceedings of the 30th Annual Meeting of the Society for Neuroscience, vol. 26. New Orleans, LA. Society for Neuroscience Abstracts, 2000. p. 236.
137. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275:2000;34393-34398.
138. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A.et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
139. Rebeck G.W. Confirmation of the genetic association of interleukin-1α with early-onset sporadic Alzheimer's disease. Neurosci. Lett. 293:2001;75-77.
140. Richard F., Amouyel P. Genetic susceptibility factors for Alzheimer's disease. Eur. J. Pharmacol. 412:2001;1-12.
141. Rochet J.C., Conway K.A., Lansbury P.T. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 39:2000;10619-10626.
142. Rodriguez Martin T., Callela A., Silva S., Munna E., Modena P., Chiesa R.et al. ApoE and polymorphism of presenilin 1 and α1-anti-chymotrypsin in Alzheimer and vascular dementia. Dementia. Geriat. Cognit. Dis. 11:2000;239-244.
143. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y.et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 778:1995;775.
144. Romero I., Jorgensen P., Bolwig G., Fraser P.E., Rogaeva E., Mann D.et al. A presenilin 1 Thr116Asn substitution in a family with early-onset Alzheimer's disease. Neuroreport. 10:1999;2255-2260.
145. Rosenberg R.N. The molecular and genetic basis of AD: the end of the beginning. Neurology. 54:2000;2045-2054.
146. Russo C., Schettini G., Saido T.C., Hulette C., Lippa C., Lannfelt L.et al. Presenilin 1 mutations in Alzheimer's disease. Nature. 405:2000;531-532.
147. Salmona M., Forloni G., Diomede L., Algeri M., De Gioia L., Angeretti N.et al. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity. Neurobiol. Dis. 4:1997;47-57.
148. Sato N., Urano F., Yoon Leem J., Kim S.H., Donovierl D., Bernstein A.et al. Up-regulation of BiP and CHOP by the unfolded protein response is idependent of presenilin expression. Nat. Cell Biol. 2:2000;863-870.
149. Saura C.A., Tomita T., Soriano S., Takahashi M., Leem J., Honda T.et al. The non-conserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced Aβ 42 production mediated by familial early-onset Alzheimer's disease-linked PS variants. J. Biol. Chem. 275:2000;17136-17142.
150. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N.et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
151. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
152. Selkoe D. Presenilin, notch and the genesis and treatment of Alzhiemer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11039-11041.
153. Serpell L.C., Berrimann J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4897-4902.
154. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823.
155. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
156. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M.et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 375:1995;754-760.
157. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S.et al. Familial Parkinson disease gene product, Parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305.
158. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R.et al. Ubiquitination of a new form of alpha-synuclein by Parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
159. Shirotani K., Takahashi K., Araki W., Maruyama K., Tabira T. Mutational analysis of intrinsic regions of presenilin 2 that determine its endoproteolytic cleavage and pathological function. J. Biol. Chem. 275:2000;3681-3686.
160. Smith M.J., Gardner R.J., Knight M.A., Forrest S.M., Beyreuther K., Storey E.et al. Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin 1 gene. Neuroreport. 10:1999;503-507.
161. Solano S.M., Miller D.W., Augood S.J., Young A.B., Penney J.B. Expression of alpha-synuclein, Parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol. 47:2000;201-210.
162. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275:2000;18344-18349.
163. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 88(3):1997;839-840.
164. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6469-6473.
165. Steiner H., Duff K., Capell A., Romig H., Grim M.G., Lincoln S.et al. A loss of function mutation of presenilin 2 interferes with amyloid β-peptide production and notch signaling. J. Biol. Chem. 274:1999;28669-28673.
166. Steiner H., Romig H., Grim M.G., Philipp U., Pesold B., Citron M.et al. The biological and pathological function of the presenilin 1 Δ exon 9 mutation is independent of its defect to undergo proteolytic processing. J. Biol. Chem. 274:1999;7615-7618.
167. Steiner H., Romig H., Pesold B., Philipp U., Baader M., Citron M.et al. Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis. Biochemistry. 38:1999;14600-14605.
168. Steiner H., Haass C. Intramembrane proteolysis by presenilins. Nat. Rev. Mol. Cell Biol. 1:2000;217-224.
169. Steiner H., Revesz T., Neumann M., Romig H., Grim M.G., Pesold B.et al. A pathogenic presenilin 1 deletion causes abberrant Aβ 42 production in the absence of congophilic amyloid plaques. J. Biol. Chem. 276:2001;7233-7239.
170. St. George-Hyslop P.H. Role of genetics in tests of genotype, status, and disease progression early-onset Alzheimer's disease. Neurobiol. Aging. 19:1998;133-137.
171. Sudoh S., Kawamura Y., Sato S., Wang R., Saido T.C., Oyama F.et al. Presenilin 1 mutations linked to familial Alzheimer's disease increase the intracellular levels of amyloid β-protein 1-42 and its N-terminally truncated variant(s) which are generated at distinct sites. J. Neurochem. 71:1998;1535-1543.
172. Sunada Y., Saito F., Matsumura K., Shimuzu T. Differential expression of the Parkin gene in the human brain and peripheral leukocytes. Neurosci. Lett. 25:1998;180-182.
173. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L. Jr., Eckman C.et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 264:1994;1336-1340.
174. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T.et al. Familial juvenile Parkinsonism: clinical and pathologic study in a family. Neurology. 44:1994;437-441.
175. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E.et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10:2001;919-926.
176. Terreni L., Calabrese E., Calella A.M., Forloni G., Mariani C. New mutation (R42P) of the Parkin gene in the ubiquitin-like domain associated with Parkinsonism. Neurology. 56:2001;463-466.
177. Tomita T., Takikawa R., Koyama A., Morohashi Y., Takasugi N., Saido T.C.et al. C terminus of presenilin is required for overproduction of amyloidogenic Aβ 42 through stabilization and endoproteolusis of presenilin. J. Neurosci. 19:1999;10627-10634.
178. Uversky V.N., Li J., Fink A.L. Evidence for a partially-folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276:2001;10737-10744.
179. van Leenwen F.W., Hol E.M. Molecular misreading of genes in Down syndrome as a model for the Alzheimer type of neurodegeneration. J. Neurol. Trans. Sup. 57:1999;137-159.
180. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P.et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the trnasmembrane aspartic protease BACE. Science. 286:1999;735-741.
181. Wegiel J., Wisniewski H.M., Kuchna I., Tarnawski M., Badmajew E., Popovitch E.et al. Cell-type-specific enhancement of amyloid-beta deposition in a novel presenilin 1 mutation (P117L). J. Neuropathol. Exp. Neurol. 57:1998;831-838.
182. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 35:1996;13709-13715.
183. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B.et al. Enhanced production and oligomerization of the 42-residue amyloid β-protein by chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272:1997;7977-7982.
184. Xia W., Ray W., Rahmati T., Kimberly T., Wolfe M., Zhang J.et al. Preselin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid β-protein generation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9299-9304.
185. Yang Y., Turner R.S., Gaut J.R. The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta 40 and Abeta 42 secretion. J. Biol. Chem. 273:1998;25552-25555.
186. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2696-2701.
187. Yu G., Nishimura M., Arawaka S., Levitan D., Zhang L., Tandon A.et al. Nicastrin mudulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature. 407:2000;48-54.
188. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13354-13359.
189. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866:2000;33-43.